{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:28:22Z","timestamp":1777555702994,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.det.2018.11.004","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T18:10:18Z","timestamp":1551809418000},"page":"229-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["What\u2019s New in Genetic Skin Diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Callie R.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Theos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2018.11.004_bib1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature03001","article-title":"Finishing the euchromatic sequence of the human genome","volume":"431","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.det.2018.11.004_bib2","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2011.253","article-title":"Next-generation diagnostics for inherited skin disorders","volume":"131","author":"Lai-Cheong","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/pde.12062","article-title":"A\u00a0review of next-generation genetic testing for the dermatologist","volume":"30","author":"Kwon","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/gim.2015.148","article-title":"Clinical application of whole-exome sequencing across clinical indications","volume":"18","author":"Retterer","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.det.2018.11.004_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/exd.12276","article-title":"Impact of next generation sequencing on diagnostics in a genetic skin disease clinic","volume":"22","author":"Takeichi","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.sder.2012.08.002","article-title":"Molecular diagnostics in genodermatoses","volume":"31","author":"Schaffer","year":"2012","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.det.2018.11.004_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/pde.13392","article-title":"A\u00a0comprehensive next-generation sequencing assay for the diagnosis of epidermolysis bullosa","volume":"35","author":"Lucky","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-016-0384-4","article-title":"Role of molecular testing in the multidisciplinary diagnostic approach of ichthyosis","volume":"11","author":"Diociaiuti","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.det.2018.11.004_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ejhg.2014.97","article-title":"Comprehensive massive parallel DNA sequencing strategy for the genetic diagnosis of the neuro-cardio-facio-cutaneous syndromes","volume":"23","author":"Justino","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.det.2018.11.004_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.det.2018.11.004_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00439-006-0308-9","article-title":"Identification of 54 large deletions\/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations","volume":"121","author":"Kozlowski","year":"2007","journal-title":"Hum Genet"},{"key":"10.1016\/j.det.2018.11.004_bib12","doi-asserted-by":"crossref","first-page":"e1005637","DOI":"10.1371\/journal.pgen.1005637","article-title":"Mosaic and intronic mutations in TSC1\/TSC2 explain the majority of TSC patients with no mutation identified by\u00a0conventional Testing","volume":"11","author":"Tyburczy","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.det.2018.11.004_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamadermatol.2014.938","article-title":"Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements","volume":"150","author":"Teng","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-017-0596-2","article-title":"mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders","volume":"12","author":"Franz","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.det.2018.11.004_bib15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pcl.2015.03.005","article-title":"Tuberous sclerosis complex","volume":"62","author":"DiMario","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.det.2018.11.004_bib16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamadermatol.2018.0465","article-title":"Topical sirolimus to treat tuberous sclerosis complex (TSC)","volume":"154","author":"Darling","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib17","series-title":"GeneReviews [Internet]","author":"Northrup","year":"1993"},{"key":"10.1016\/j.det.2018.11.004_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","article-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibromas lesions in a patient with tuberous sclerosis","volume":"159","author":"Hofbauer","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","article-title":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","volume":"73","author":"Nathan","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib20","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.det.2018.11.004_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/archdischild-2016-312001","article-title":"Cutaneous manifestations of tuberous sclerosis complex and the paediatrician\u2019s role","volume":"102","author":"Cardis","year":"2017","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.det.2018.11.004_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","article-title":"Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex \u2013 a comprehensive review of the literature","volume":"61","author":"Jozwiak","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.det.2018.11.004_bib24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","article-title":"Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomize clinical trial","volume":"154","author":"Koenig","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamadermatol.2014.4298","article-title":"Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex","volume":"151","author":"Wataya-Kaneda","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib26","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamadermatol.2014.87","article-title":"Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin","volume":"150","author":"Muzic","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib27","first-page":"1095","article-title":"Sun exposure causes somatic-hit mutations and angiofibroma development in tuberous sclerosis complex","volume":"150","author":"Tyburczy","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1940-6207.CAPR-15-0419","article-title":"Inhibition of Akt enhances the chemopreventive effects of topical rapamycin in mouse skin","volume":"9","author":"Dickinson","year":"2016","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.det.2018.11.004_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2009.11.020","article-title":"Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009","volume":"63","author":"Oji","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib30","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14514.1","article-title":"Recent advances in understanding inherited disorders of keratinization","volume":"7","author":"Zaki","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.det.2018.11.004_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2310\/7750.2012.12018","article-title":"Familial pityriasis rubra pilaris: case report and review","volume":"17","author":"Mercer","year":"2013","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2018.11.004_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.det.2018.11.004_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.15462","article-title":"Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14","volume":"178","author":"Lwin","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.det.2018.11.004_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjd.12952","article-title":"Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14","volume":"171","author":"Eytan","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.2010.09855.x","article-title":"Treatment of pityriasis rubra pilaris with ustekinumab","volume":"163","author":"Wohlrab","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1346-8138.14114","article-title":"Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases","volume":"45","author":"Napolitano","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jdcr.2017.09.010","article-title":"Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl","volume":"4","author":"Bonomo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2018.11.004_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaad.2018.02.034","article-title":"CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris","volume":"79","author":"Craiglow","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17-dominant immune profile is shared across the major orphan forms of ichthyoses","volume":"139","author":"Paller","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.det.2018.11.004_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2018.03.1523","article-title":"The major orphan forms of ichthyoses are characterized by systemic T-cell activation and Th-17\/Tc-17\/Th-22\/Tc-22 polarization in blood","author":"Czarnowicki","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib42","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaad.2017.10.026","article-title":"The spectrum of manifestations in desmoplakin gene (DSP) spectrim repeat 6 domain mutations: immunophenotyping and response to ustekinumab","volume":"78","author":"Paller","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/exd.12826","article-title":"Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Vahidnezhad","year":"2016","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.11.004_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41419-017-0064-x","article-title":"PI3K\/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations","volume":"9","author":"di Blasio","year":"2018","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.det.2018.11.004_bib45","doi-asserted-by":"crossref","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.det.2018.11.004_bib46","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamadermatol.2016.1008","article-title":"Life-threatening cutaneous bleeding in childhood Klippel-Trenaunay syndrome treated with oral sirolimus","volume":"152","author":"Bessis","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.det.2018.11.004_bib48","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","article-title":"Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus","volume":"94","author":"Kim","year":"2016","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.det.2018.11.004_bib49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamadermatol.2015.0251","article-title":"Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood granulomatosis with polyangitis","volume":"151","author":"Munoz","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","article-title":"Type 1 interferonopathies: mendelian type I interferon up-regulation","volume":"32","author":"Crow","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.det.2018.11.004_bib51","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1172\/JCI121526","article-title":"JAK inhibitors in autoinflammation","volume":"128","author":"Hoffman","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.det.2018.11.004_bib52","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/1 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.det.2018.11.004_bib53","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the\u00a0treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fremond","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.det.2018.11.004_bib54","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING","volume":"76","author":"Konig","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2018.11.004_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MOP.0000000000000514","article-title":"Genetic diseases associated with an increased risk of skin cancer development in childhood","volume":"29","author":"Fogel","year":"2017","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.det.2018.11.004_bib56","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/ajmg.a.34128","article-title":"Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS)","volume":"155A","author":"Bree","year":"2011","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.det.2018.11.004_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-016-0506-z","article-title":"Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials","volume":"11","author":"Chang","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.det.2018.11.004_bib58","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.11.004_bib59","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.11.004_bib60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","article-title":"Expanded access study of patients with advanced basal cell carcinoma treated with Hedgehog pathway inhibitor, vismodegib","volume":"70","author":"Chang","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib61","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","article-title":"Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Tang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.det.2018.11.004_bib62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamadermatol.2015.3210","article-title":"Intermittent vismodegib therapy in basal cell nevus syndrome","volume":"152","author":"Yang","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib63","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomized, regimen-controlled, double blind, phase 2 trial","volume":"18","author":"Dreno","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.det.2018.11.004_bib64","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jid.2017.09.048","article-title":"Genomic stability in syndromic basal cell carcinoma","volume":"138","author":"Chiang","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib65","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jdcr.2017.11.011","article-title":"Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: clinical approach and genetic analysis","volume":"4","author":"Sinx","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2018.11.004_bib66","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng.3525","article-title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","volume":"48","author":"Bonilla","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.det.2018.11.004_bib67","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1067\/mjd.2001.112399","article-title":"Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome","volume":"44","author":"Chiritescu","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/pde.13080","article-title":"Vismodegib therapy for basal cell carcinoma in an 8-year-old Chinese boy with xeroderma pigmentosum","volume":"34","author":"Fife","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib69","doi-asserted-by":"crossref","first-page":"69295","DOI":"10.18632\/oncotarget.20619","article-title":"Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor","volume":"8","author":"Robinson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.det.2018.11.004_bib70","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/neuonc\/nox109","article-title":"Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma","volume":"19","author":"Kieran","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.det.2018.11.004_bib71","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1056\/NEJMoa1213507","article-title":"Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ","volume":"368","author":"Shirley","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2018.11.004_bib72","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jid.2015.11.027","article-title":"Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis","volume":"136","author":"Thomas","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pde.13273","article-title":"Epidermal nevus syndromes: new insights into whorls and swirls","volume":"35","author":"Asch","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ajmg.a.37439","article-title":"The categories of cutaneous mosaicism: a proposed classification","volume":"170A","author":"Happle","year":"2016","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.det.2018.11.004_bib75","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2013.24","article-title":"Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell","volume":"133","author":"Groesser","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/ddt429","article-title":"Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia","volume":"23","author":"Lim","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.det.2018.11.004_bib77","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.11.012","article-title":"Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy","volume":"75","author":"Lim","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib78","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/jid.2013.70","article-title":"Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 or NRAS","volume":"133","author":"Kinsler","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2018.11.004_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ajhg.2016.02.006","article-title":"Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis","volume":"98","author":"Bennett","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.det.2018.11.004_bib80","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/ajmg.a.37048","article-title":"Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations","volume":"167","author":"Peacock","year":"2015","journal-title":"Am J Med Genet A"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T02:10:54Z","timestamp":1554689454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518311422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0733863518311422"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.11.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s New in Genetic Skin Diseases","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}